SCHEMBL25873240

SCHEMBL25873240

CC(C)NC(=O)c1ccc2c(c1)CCN(C(C)C)C2

nearest known ligand 0.50

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.50
HDAC6 Q9UBN7 7/20 0.48
HDAC8 Q9BY41 2/20 0.48
PTGER1 P34995 1/20 0.46
SMYD3 Q9H7B4 1/20 0.46
TP53 P04637 1/20 0.44
HRH3 Q9Y5N1 3/20 0.43
HDAC3 O15379 1/20 0.43
HDAC1 Q13547 1/20 0.43
ACACB O00763 1/20 0.43
KMT2A Q03164 2/20 0.41
ALDH1A1 P00352 1/20 0.41
HSP90AA1 P07900 1/20 0.41
GAA P10253 1/20 0.41
MEN1 O00255 1/20 0.41
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3879495 0.85 ACACB (0.54) HDAC6HDAC8PTGER1HRH3ACACB
SCHEMBL20173793 0.83 ALDH1A1 (0.51) HDAC6HDAC8PTGER1HRH3ALDH1A1
SCHEMBL20173805 0.82 HDAC6 (0.44) HDAC6HDAC8PTGER1ALDH1A1HSP90AA1
SCHEMBL13791770 0.82 HDAC6 (0.42) HDAC6HDAC8PTGER1HRH3HDAC3
SCHEMBL26167813 0.82 PTGER1 (0.44) HDAC6HDAC8PTGER1HRH3HDAC3
SCHEMBL26161462 0.82 HSD17B3 (0.51) POLBHDAC6HDAC8PTGER1HRH3
Hydrochloric Acid SCHEMBL3880242 0.81 PTGER1 (0.43) HDAC6HDAC8PTGER1HRH3HDAC3
SCHEMBL20173800 0.80 HDAC6 (0.46) HDAC6HDAC8PTGER1HDAC3HDAC1
SCHEMBL21882599 0.80 HDAC6 (0.43) POLBHDAC6HDAC8PTGER1HSP90AA1
SCHEMBL4520343 0.80 HRH3 (0.55) HRH3ALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230227826-A1 UNA OLIGOMERS FOR THE TREATMENT OF POLYGLUTAMINE DISEASES ARCTURUS THERAPEUTICS, INC. 2023-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230227826-A1 UNA OLIGOMERS FOR THE TREATMENT OF POLYGLUTAMINE DISEASES HNRNPR, HNRNPK, ATXN2 POLB 1561/4885HDAC6 1182/4885HDAC8 923/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.